Share

July 10, 2012; 79 (2) Articles

Falls and fractures in patients chronically treated with antiepileptic drugs

Baemisla Shiek Ahmad, Keith David Hill, Terence John O'Brien, Alexandra Gorelik, Natalie Habib, John Dennis Wark
First published June 13, 2012, DOI: https://doi.org/10.1212/WNL.0b013e31825f0466
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
449

Share

Article Information

vol. 79 no. 2 145-151
DOI: 
https://doi.org/10.1212/WNL.0b013e31825f0466
PubMed: 
22700806
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received June 13, 2011
  • Accepted December 8, 2011
  • First Published June 13, 2012.

Article Versions

Copyright & Usage: 
Copyright © 2012 by AAN Enterprises, Inc.

Author Disclosures

    1. Baemisla Shiek Ahmad, MD,
    2. Keith David Hill, PhD,
    3. Terence John O'Brien, MD,
    4. Alexandra Gorelik, MSc,
    5. Natalie Habib, PhD and
    6. John Dennis Wark, PhD
  1. Baemisla Shiek Ahmad, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Dr Baemisla receives support for her PhD from University of Malaya; Ministry of Higher Education (MOHE), Malaysia.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Keith David Hill, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Department of Veterans’ Affairs, 2011-12; NHMRC project grant; , 2011-2014

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Skobie MacKinnon Fund

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Terence John O'Brien, MD,
    4. Scientific Advisory Boards:

    1. Janssen-Cilag, Chair, Neurolept advisory board, 2008

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. UCB Pharma, speaker honoraria; Sanofi, speaker honoraria; Sigen, speaker honoraria

    Editorial Boards:

    1. Epilepsia (2007-9); Journal of Clinical Neuroscience; ; Epilepsy and Behavior;

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Educational symposia:; Janssen-Cilag 2008&9; Sanofi-Aventis 2009

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. UCB; Abbott

    Research Support, Government Entities:

    1. NHMRC Project grants (Australia) 2008-11

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. RMH Neuroscience Foundation, NARSAD 08, 09; Epilepsy Research Foundation 2009

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Alexandra Gorelik, MSc,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Natalie Habib, PhD and
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. John Dennis Wark, PhD
    7. Scientific Advisory Boards:

    1. Amgen/GSK; Novartis; Lactopharma

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1.) Servier, travel grant for conference and investigator meeting attendance; Servier, speaker honoraria; Amgen, speaker honoraria; Novartis, speaker honoraria; Sanofi-Aventis, speaker honoraria; Eli Lilly, speaker honoraria; Merck, Sharp and Dohme, speaker honoraria

    Editorial Boards:

    1. Clinical Science, specialist editor, 1999 - 2008 2. Osteoporosis International, editorial board member, 2005 - current; Journal of Osteoporosis, editorial board member, 2008 - current

    Patents:

    1. NONE

    Publishing Royalties:

    1. Physical Activity and Bone Health, Human Kinetics Publishers, Champaign, 2001

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Vactec; AstraZeneca Speakers’ Bureaus:; Servier; Amgen; Novartis; Sanofi-Aventis; Eli Lilly; Merck, Sharp and Dohme

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. Royal Melbourne Hospital Bone Densitometry Unit, bone densitry testing, 10%, 1988 - present

    Research Support, Commercial Entities:

    1. Novartis; UCB Pharma; Sanofi-Aventis; Eli Lilly

    Research Support, Government Entities:

    1. National Health and Medical Research Council of Australia, multiple grants, chief investigator, 2009 - present; Victorian Cancer Agency, chief investigator, 2010 - present; ANZ Trustees, investigator, 2009 - 2010

    Research Support, Academic Entities:

    1. Monash University; LaTrobe University

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Medicine (B.S.A., T.J.O., N.H., J.D.W.), Department of Neurology (T.J.O.), and Melbourne EpiCentre (A.G.), Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria; Musculoskeletal Research Centre and School of Physiotherapy (K.D.H.), La Trobe University and Northern Health, Bundoora, Victoria; National Ageing Research Institute (K.D.H.), Parkville, Victoria; The Royal Melbourne Hospital Bone and Mineral Service (J.D.W.), Parkville, Victoria; School of Physiotherapy (K.D.H.), Curtin University, Perth, Western Australia, Australia; and Department of Physiology (B.S.A.), Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
  1. Correspondence & reprint requests to Dr. Wark: jdwark{at}unimelb.edu.au
View Full Text

Article usage

Article usage: June 2012 to April 2019

AbstractFullPdfSource
Jun 2012304017Highwire
Jul 201216205799Highwire
Aug 2012262151133Highwire
Sep 2012981120Highwire
Oct 201280108Highwire
Nov 20125635Highwire
Dec 20124668Highwire
Jan 20136556Highwire
Feb 20135536Highwire
Mar 20134655Highwire
Apr 201341910Highwire
May 20133273Highwire
Jun 20134064Highwire
Jul 20133543Highwire
Aug 20133123Highwire
Sep 20132513Highwire
Oct 20133035Highwire
Nov 20134313Highwire
Dec 20131733Highwire
Jan 20141723Highwire
Feb 20142768Highwire
Mar 20144453Highwire
Apr 20143559Highwire
May 20142756Highwire
Jun 20143355Highwire
Jul 20144311Highwire
Aug 20144102Highwire
Sep 20144211Highwire
Oct 20146100Highwire
Nov 20145340Highwire
Dec 20145540Highwire
Jan 20154931Highwire
Feb 20155822Highwire
Mar 20155403Highwire
Apr 20154936Highwire
May 20155745Highwire
Jun 20155312Highwire
Jul 20154311Highwire
Aug 20155600Highwire
Sep 20154904Highwire
Oct 20154912Highwire
Nov 20154201Highwire
Dec 20154022Highwire
Jan 20163601Highwire
Feb 20162300Highwire
Mar 20161501Highwire
Apr 20161400Highwire
May 20161401Highwire
Jun 20163103Highwire
Jul 20161800Highwire
Aug 20161711Highwire
Sep 20161821Highwire
Oct 20162822Highwire
Nov 20162733Highwire
Dec 20162001Highwire
Jan 20171211Highwire
Feb 20171710Highwire
Mar 20171911Highwire
Apr 20171800Highwire
May 20172600Highwire
Jun 20171601Highwire
Jul 20171400Highwire
Aug 20172800Highwire
Sep 20171210Highwire
Oct 20176110Highwire
Nov 20171411Highwire
Dec 20172510Highwire
Jan 20182852Highwire
Feb 20183700Highwire
Mar 20184130Highwire
Apr 20185200Highwire
May 20183201Highwire
Jun 20186221Highwire
Jul 20184200Highwire
Aug 20183111Highwire
Sep 20183900Highwire
Oct 20184801Highwire
Nov 20185321Highwire
Dec 20185615Highwire
Jan 20196102Highwire
Feb 20196511Highwire
Mar 20195101Highwire
Apr 20194204Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me